Introduction: Pain management during the postoperative period following total knee arthroplasty (TKA) remains challenging. Epidural analgesia and femoral nerve blockade are commonly used, and while effective at controlling postoperative pain, these have undesirable side effects, including nausea, hypotension, pruritis, somnolence, dizziness, and respiratory depression [1] . As a result, a number of authors have advocated a multimodal approach with the inclusion of peri-or intra-articular local anesthetics. The efficacy of periarticular analgesic injections following total knee replacement is controversial [2] [3] [4] [5] , and that of continuous infusion intra-articular anesthetics remains largely unknown. The purpose of this study was to compare the side effect profile and analgesic efficacy of a continuous intra-articular infusion of ropivacaine to an epidural plus femoral nerve block following total knee replacement. Materials and Methods: Eighty-six patients undergoing unilateral TKA were prospectively randomized to receive a 48-h continuous postoperative intra-articular infusion of 0.2 ropivacaine (7 cc/h) (group R) or to receive an epidural analgesic (250 cc Dilaudid 10 mcg-bupivacaine 0.06%) plus a single injection femoral nerve block (30 cc 0.25% bupivacaine) (group E). All patients were blinded to their treatment and received placebo saline intra-articular (group E) or epidural catheters (group R). Blinded co-investigators collected data on side effects (episodes of nausea and hypotension), analgesic efficacy (maximum numerical pain rating scores and narcotic consumption in morphine equivalents), functional outcomes (Timed Get-Up-and-Go [TGUG] test and handheld dynanometer quadriceps strength testing) and patient-based outcome scores (Knee Society Score and WOMAC Osteoarthritis Index). Intention-to-treat analyses were performed for all randomized participants. Results: Forty-one patients were randomized to group R and 45 patients to group E. Baseline demographics were similar between groups. During the postoperative period, the mean number of episodes of nausea and hypotension, as well as the percent of patients who reported experiencing at least one episode of each, was not significantly improved in group R compared to group E. Mean maximum numerical pain rating scores were not significantly different between groups, except on postoperative day1 where pain scores in group E (1.28± 2.52) were significantly better than in group R (4.23±3.07) (p=0.00001). Mean total narcotic usage prior to discharge from the hospital in group R (121±70 mg) was not significantly different from group E (135±151 mg) (p=0.579). At all time points, peak voluntary quadriceps strength, and torque (percent of nonoperative leg) were not significantly different between groups and returned to normal by 6 weeks postoperatively in both groups. Mean TGUG in group R on the day of discharge (30±14 s) was not found to be significantly better than in group E (40±42 s) (p=0.175) and returned to preoperative values by 6 weeks postoperatively in both groups. Knee Society Scores and WOMAC indices were similar between groups at all time points up to 3 months postoperatively. A fall during the hospital stay was experienced by 22% of patients in group E and 15% of patients in group R. No difference in length of stay was found between groups (p=0.842). Complication rates were similar, and no infections occurred in either group up to 3 months postoperatively. Conclusions: In the current level I study, a continuous intraarticular infusion of ropivacaine following TKA demonstrated a similar side effect profile, similar quadriceps strength recovery, and similar functional recovery, but worse analgesic efficacy during the first 24 h postoperatively when compared to an epidural plus femoral nerve block. While epidural plus femoral nerve block remains our "gold standard," in patients where an epidural is not possible, an intra-articular infusion of ropivacaine can be recommended as a safe and effective alternative, particularly if combined with a femoral nerve block for enhanced analgesia during the first 24 postoperative hours. 
Introduction:
Bisphosphonates are currently the predominant medical treatment option for patients with osteogenesis imperfecta [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] ; however, concerns exist over long-term bisphosphonate therapy [11] [12] [13] [14] . The objective of this study was to determine the effect of treatment with parathyroid hormone (PTH), alendronate (ALN), and the combination of PTH followed by alendronate (PTH + ALN) on bone mechanical properties, morphology, and fracture number in an oim/oim mouse model.
Materials and Methods:
Four-week-old oim/oim and wild type (+/+, WT) mice were randomized into four groups (n=17/group). The mice were weighed daily and subcutaneously injected five times per week for a period of 12 weeks with (1) saline, (2) PTH, (3) ALN, or (4) PTH for 6 weeks, followed by ALN for 6 weeks (PTH + ALN). The mice were euthanized after 12 weeks of treatment, and Faxitron images were obtained to determine the number of fractures in appendicular skeleton. Trabecular and cortical bone analysis was performed on the femora using micro-computed tomography. Finally, specimens were mechanically tested to failure using three-point bending.
Results: All pharmacologic treatments significantly reduced the number of fractures seen in oim/oim mice compared to salinematched controls (p<0.05). However, average fracture numbers were not different between treatment groups (PTH=3.17 vs. ALN=2.53 vs. PTH + ALN=2.80). In WT mice, treatment with alendronate alone led to fragile bone, as evidenced by a significant decrease in energy absorbed to failure and an increased bending stiffness (p<0.05). In the oim/oim mice, treatment with both ALN and PTH + ALN led to significant increases in trabecular BV/TV and trabecular number, but no pharmacologic therapy was able to significantly increase trabecular TMD. Further, PTH + ALN significantly increased cortical bone area to levels comparable to WT mice treated with saline. Finally, in oim/oim mice, PTH + ALN drastically improved the energy absorbed to failure and failure moment of whole bone to levels that were not significantly different than wild-type bone (p>0.05).
Conclusions:
In oim/oim mice, treatment with parathyroid hormone, alendronate, or a combination of both agents reduced the numbers of skeletal fractures. However, PTH + ALN resulted in marked improvement in the bone morphology with similar mechanical properties to that of WT bone and ameliorated the brittle bone seen with treatment with ALN alone, which may ultimately prove to be most beneficial to patients with osteogenesis imperfecta.
References: Introduction/Background: Cerebral blood flow (CBF) is believed to decline when mean arterial blood pressure (MAP) is <70 mmHg. Hypotensive epidural anesthesia (HEA) employs deliberate reduction of mean arterial pressure to ≤50 mmHg by epidural anesthetic-induced sympatholysis, with the simultaneous infusion of epinephrine to maintain the cardiac output. This technique has been associated with normal postoperative cognitive function suggesting that CBF is not adversely affected by MAP ≤50 mmHg and that physiologic parameters other than MAP might influence cerebral hemodynamics. Previous investigations have shown that epinephrine infusion during HEA increases stroke volume and cardiac index while decreasing systemic vascular resistance and MAP, but were limited by the inability to monitor cerebral function. Therefore, the present study sought to investigate cerebral blood flow velocity (CBFV) with transcranial Doppler under HEA. Materials & Methods: Sixty-one patients undergoing total hip arthroplasty with HEA were enrolled in this prospective observational study. Following sedation with midazolam and propofol, epidural anesthesia was performed in the lateral decubitus position via the paramedian approach at the L1-L2 interspace by injection of 25-30 ml of a mixture of 2% lidocaine and 0.75% bupivacaine via a 17-gauge Weiss needle to achieve an anesthetic level at T4 or above. Epinephrine infusion through a central venous catheter was initiated immediately after the epidural injection and the infusion rate was adjusted (1-8 μg/ min) to achieve an MAP at 50 mmHg. Continuous arterial blood pressure, heart rate, ECG, central venous pressure, and end-tidal pCO 2 as sampled from a nasal cannula were monitored continuously. CBFV in the middle cerebral artery was measured by transcranial Doppler ultrasonography with a 2-MHz probe (Sonara TCD, CareFusion, WI) using a transtemporal window. Data were recorded with the patients awake and after propofol-induced sedation in the supine position. Patients were then placed in the lateral decubitus and remained in this position throughout surgery. Data were analyzed at specific time points prior and during HEA and following ephedrine injection at the end of surgery. A univariate analysis with a paired t test and a multivariate linear regression based on the generalized estimating equations were used to analyze the data. Results: Fifty-two patients (34 men, 18 women, age 59± 11 years, height 174±11 cm, weight 87±22 kg, and ASA I/ II/II 10/29/13, respectively) completed the study. EtCO 2 (mean between 37 and 39 mmHg), CVP, SpO 2 , and HR remained unchanged throughout HEA. Multivariate regression analysis was performed to identify any influence of demographic variables, comorbidities, intra-procedure physiologic parameters, and protocol-related variables on CBFV during the hypotensive anesthesia. The peak CBFV was higher during HEA 1, 2, and 3 as compared to baseline (p =0.01, 0.003, and <0.0001, respectively), the mean CBFV remained unchanged (p=0.42, 0.97, and 0.94, respectively) and the end-diastolic CBFV was lower (p=<0.0001 for all the three HEA intervals). The pulsatility index (PI) did not change at HEA 1 and 2 but was higher at HEA 3 as compared to baseline (p=0.41, 0.12, and 0.009, respectively). Female gender was associated with higher peak, mean, and diastolic CBFV (p=0.01, 0.007, and 0.01 respectively). The use of beta blockers was associated with lower peak, mean, and PI CFBV (p=0.005, 0.004, and 0.02, respectively). The presence of cardiovascular disease was not associated with any changes in mean and peak CBFV, but diastolic CBFV and pulsatility index were lower in that subgroup of patients (p=0.03 and 0.001, respectively). The higher the heart rate, the lower the peak and mean CBFV (p=0.003 and 0.007, respectively). Age, obesity class, pre-epidural MAP values, MAP, and rate of epinephrine infusion showed no effect on any of the CBFV parameters. There was no correlation between mean CBFV and MAP for values of MAP ranging from 100 to 40 mmHg (R 2 =0.0015, p=0.44).
Discussion: The present investigation demonstrates preservation of CBFV at MAPs commonly viewed as well below the lower limit of cerebral autoregulation. Although the study does not allow us to address the relevance of the maintenance of cardiac output by epinephrine to the preservation of CBF that we observed, we speculate that cardiac output effects are of critical importance in maintaining CBF independent of cerebral autoregulation. 
